Squarepoint Ops LLC Sells 46,982 Shares of Altimmune, Inc. (NASDAQ:ALT)

Squarepoint Ops LLC lowered its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 76.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 14,706 shares of the company's stock after selling 46,982 shares during the period. Squarepoint Ops LLC's holdings in Altimmune were worth $106,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of ALT. Two Sigma Investments LP boosted its holdings in shares of Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock valued at $4,364,000 after acquiring an additional 151,001 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in Altimmune by 1.3% during the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company's stock valued at $1,137,000 after purchasing an additional 1,964 shares in the last quarter. ProShare Advisors LLC boosted its stake in Altimmune by 74.1% during the 4th quarter. ProShare Advisors LLC now owns 23,371 shares of the company's stock valued at $169,000 after purchasing an additional 9,950 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Altimmune by 22.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,899 shares of the company's stock valued at $194,000 after purchasing an additional 4,851 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Altimmune by 139.8% in the 4th quarter. Millennium Management LLC now owns 345,637 shares of the company's stock worth $2,492,000 after buying an additional 201,484 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, April 3rd. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Finally, Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.20.

Altimmune Stock Up 13.3%

Shares of Altimmune stock traded up $0.79 on Tuesday, hitting $6.74. 7,949,854 shares of the company traded hands, compared to its average volume of 2,851,375. Altimmune, Inc. has a 12-month low of $3.55 and a 12-month high of $11.16. The company has a 50-day moving average price of $5.13 and a 200 day moving average price of $6.31. The company has a market cap of $546.66 million, a PE ratio of -4.35 and a beta of 0.58.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the prior year, the firm posted ($0.34) EPS. Equities research analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.